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Abstract Cerebellar cysts are rare findings in pediatric neuro-
imaging and rather characteristic for dystroglycanopathies and
GPR56-related encephalopathy. We aim to report on seven
children with cerebellar cysts showing absence of weakness
and ruling out mutations within eight dystroglycanopathy genes
and GPR56 . Data about neurological and ophthalmological
features, outcome, and creatine kinase valueswere collected from
clinical histories and follow-up examinations. All MR images
were qualitatively evaluated for infra- and supratentorial abnor-
malities. A SNP 6.0-Array was performed in three children. The
POMT1 , POMT2, POMGnT1 , FKRP, FKTN , LARGE , ISPD ,
B3GALNT2 , and GPR56 genes were screened in all patients by
Sanger sequencing. Seven children from five families were
studied. Ataxia, intellectual disability, and language impairment
were found in all patients, ocular motor apraxia in five, and
severe myopia in three. None of the patients had weakness, only
three a minimally increased creatine kinase value. Qualitative
neuroimaging evaluation showed cerebellar cysts and dysplasia
in the cerebellar hemispheres and vermis in all children.
Additional findings were an enlarged fourth ventricle in all
children, vermian hypoplasia and brain stem morphological ab-
normalities in five. The SNP array showed no pathogenetic
imbalances in all children evaluated. In all patients, no mutations
were found in POMT1, POMT2 , POMGnT1 , FKRP, FKTN ,
LARGE , ISPD , B3GALNT2 , and GPR56. The peculiar combi-
nation of the same clinical and neuroimaging findings in
our patients highly suggests that this phenotype may represent
a novel entity, possibly falling within the spectrum of
dystroglycanopathies.
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Introduction
Cerebellar cysts are rare findings in pediatric neuroimaging
[1]. They are a rather specific imaging finding for congenital
muscular dystrophies (CMDs) because of defective glycosyl-
ation of α-dystroglycan [2].
CMDs are clinically and genetically heterogeneous with a
variable involvement of brain, eyes, and muscles [3, 4]. At the
most severe end of the spectrum are Walker–Warburg syn-
drome (WWS), muscle–eye–brain (MEB) disease, and
Fukuyama CMD (FCMD). These syndromes are character-
ized by muscle weakness, hypotonia and in some cases con-
tractures at birth or within the first 6 months of life, brain
malformations (e.g., cobblestone brain as well as cerebellar
and brain stem anomalies) resulting in impaired cognitive and
motor development, and seizures and eye involvement (e.g.,
retinal dysplasia and microophthalmia) [2–6]. At the mildest
end of the phenotypic spectrum, however, affected patients
may present first in adult life with limb–girdle distribution of
their muscle weakness without associated brain or eye in-
volvement [7].
To date, mutations in 15 genes involved in glycosylation of
α-dystroglycan have been associated with CMDs [4, 5, 8–11].
Mutations in these genes account for about half of the patients
[3–5]. Additionally, mutations within the GPR56 gene may
result in a cobblestone-like lissencephaly with cerebellar cysts
[12].
Here, we report on neurological and ophthalmological
features, neurodevelopmental outcome, neuroimaging find-
ings, and results of molecular genetic analysis of seven chil-
dren with a distinctive phenotype characterized by ataxia,
intellectual disability, ocular motor apraxia, cerebellar cysts,
and cerebellar dysplasia. We hypothesize that these children
may represent a new disease, possibly a new phenotype within
the dystroglycanopathy spectrum.
Patients and Methods
This retrospective study did not require approval by the
Institutional Review Board. Informed consent for molecular
genetics analyses was obtained from the parents of all children
included.
Patient Cohort
The patients included in this studywere collected by the senior
investigator (EBo) from three sources: (1) his personal data-
base of patients with cerebellar cysts, (2) data of patients with
cerebellar cysts referred to EBo for second opinion, and (3)
collaboration with other clinical professionals who contribut-
ed cases.
The inclusion criterion for this retrospective study was the
presence of cysts within the cerebellum on MR images.
Exclusion criteria were (1) the presence of cerebellar cysts in
children with the diagnosis of well-defined α-dystrogly-
canopathies (clinical and neuroimaging diagnosis with genetic
confirmation) and (2) other defined disorders associated with
cerebellar cysts including Aicardi syndrome (clinical and neu-
roimaging findings) [13, 14] and pontocerebellar hypoplasia
type 6 (clinical and neuroimaging findings) [15].
Clinical Analysis
Review of the clinical histories and clinical–neurological
follow-up examinations provided detailed information about
neurological and ophthalmological features as well as
neurodevelopmental outcome. Whenever possible, the cogni-
tive and language outcome was evaluated by a formal neuro-
psychological testing with assessment of the intelligence quo-
tient (IQ) or a standardized developmental testing with assess-
ment of the developmental quotient (DQ). Otherwise, the
developmental stage was estimated from the patient’s history,
clinical observations, and kindergarten or school reports.
These details are listed in Table 1.
Qualitative Neuroimaging Analysis
In a retrospective analysis, two pediatric neurologists with
experience in neuroimaging of the pediatric cerebellum (AP
and EBo) and a pediatric neuroradiologist (TAGMH) qualita-
tively analyzed all available neuroimaging data sets. The
parameters chosen for evaluation are listed in Table 2.
Cerebellar dysplasia was defined as an abnormal cerebellar
foliation, fissuration and white matter arborization. The brain
stem was assessed on sagittal images according to Doherty
et al [16].
Molecular Genetic Analysis
Genetic analyses included (1) molecular genotyping by using
single nucleotide polymorphism (SNP) array with an Affymetrix
GeneChip®Genome-Wide Human SNP 6.0-Array (patients 1, 3,
and 7; this analysis was not available for the remaining patients)
and (2) direct mutation analysis of the coding exons and flanking
sequencing of the following genes (all patients): POMT1
(GenBank accession number NM_007171.3), POMT2
(NM_013382.4), POMGnT1 (NM_017739.2), FKRP
(NM_001039885.1), FKTN (NM_006731.2), LARGE
(NM_004737.3), ISPD (NM_001101426.3), B3GALNT2
(NM_152490.3), and GPR56 (NM_005682).
For mutation analysis, genomic DNA was prepared from
peripheral blood samples from patients and available family
members according to standard protocols. Sequencing of coding
regions and flanking intronic sequences for all analyzed genes
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was performed on PCR products after amplification of genomic
DNA using oligonucleotide primers and PCR conditions avail-
able upon request, and cycle-sequencing adopting the BigDye
3.1 chemistry (Applied Biosystems, Foster City, CA) and fol-
lowing the consensus guidelines for mutation nomenclature
(www.hgvs.org/mutnomen). All possible new variants were
searched for in a large set of in-house control chromosomes as
well as in dbSNP database (http://www.ncbi.nlm.nih.gov/
projects/SNP/) and Exome Variant databases (http://evs.gs.
washington.edu/EVS/; https://genomics.med.miami.edu/gvd-hd/
dataSearch.php). New variations were also systematically
evaluated in silico to predict their effects on protein function
with Condel (http://bg.upf.edu/condel/), Polyphen analysis
(http://genetics.bwh.harvard.edu/pph2/index.shtml), and
Mutation Taster (http://www.mutationtaster.org/).
Results
Patient Characteristics and Clinical Findings
Seven patients (fourmales and three females) from five unrelated
families who showed cerebellar cysts on neuroimaging and
fulfilled the above mentioned inclusion criteria were included
in this study. At the last follow-up, the median age was 7.5 years
(mean, 7.8 years; range, 4.0 to 14.0 years). Pregnancy was
uneventful in all children. Patient 7was born preterm at 36weeks
of gestation. His delivery and perinatal history were uneventful.
The most prominent clinical findings were ataxia (n =7),
intellectual disability (n =7), delayed speech/language devel-
opment (n =7), and ocular motor apraxia (OMA; n =5). The
creatine kinase (CK) was elevated in three children. Albumin
has been measured in two children and was normal in both. α-
fetoprotein and cholesterol have been measured in one child
and were both normal. More detailed neurological and oph-
thalmological characteristics are summarized in Table 1.
The cognitive functions of patient 1 were assessed by the
non-verbal Snijders-Oomen Nonverbal Intelligence Test
(SON-R 2.5-7) at the age of four years. His IQ was 70. The
cognitive functions of patient 3 were assessed by the third
edition of the Wechsler Preschool and Primary Scale of
Intelligence (WPPSI) at the age of six years. His IQ was 69.
If available, detailed data on the motor and/or cognitive de-
velopment are reported for all patients without a standardized
cognitive/developmental test. At the age of 4.6 years, the DQ
of patient 2 was estimated to be about 60. She spoke less than
ten words. Finally, patient 7 started to walk independently at
the age of 3.5 years.
Qualitative Neuroimaging Findings
All children showed cortical–subcortical cerebellar cysts (bi-
lateral, six of seven) affecting the vermis and the hemispheres
as well as bilateral cerebellar dysplasia. Supratentorial migra-
tional disorders and white matter signal abnormalities, by
contrast, were not recorded. More detailed results of the
qualitative neuroimaging analysis of each patient’s MRI (me-
dian age of 3.8 years; mean, 3.7 years; range, 3 months to
10.5 years) are summarized in Table 2. Representative images
are shown in Figs. 1, 2, 3, 4, and 5.
Molecular Genetics Findings
Molecular genotyping by SNP array did not show pathoge-
netic imbalances in all children evaluated (patients 1, 3, and
7). Variants of disease significance could not be detected in the
POMT1 , POMT2 , POMGnT1 , FKRP, FKTN , LARGE ,
ISPD , B3GALNT2 , and GPR56 coding exons and flanking
intronic sequences in all patients.
Discussion
We report on seven children with the same clinical and imag-
ing phenotype characterized by (1) brain involvement as a
cerebellar syndrome with nonprogressive ataxia, OMA, and
intellectual disability and (2) cerebellar cysts and cerebellar
dysplasia. To the best of our knowledge, this peculiar combi-
nation of clinical and neuroimaging findings has not been
previously reported and may represent a novel syndromic
entity. The affection of three siblings (two females and one
male) suggests a genetic disorder with autosomal recessive
inheritance.
Clinical Phenotype
The clinical presentation in our patients is characterized by a
cerebellar syndrome including nonprogressive ataxia, OMA,
and intellectual disability. Intellectual disability and non-
progressive cerebellar ataxia are non-specific features of sev-
eral diseases [17–19]. The differential diagnosis of OMA is,
however, shorter [20]. OMA and nonprogressive cerebellar
ataxia typical clinical features of Joubert syndrome [21] and
congenital OMA-type Cogan [22]. Additionally, they have
been rarely reported in other brain malformations such as
agenesis of the corpus callosum and brain stem dysgenesis
[23]. These disorders can be easily excluded in our patients
because (1) the characteristic neuroimaging findings such as
the molar tooth sign in Joubert syndrome and a hypoplastic or
normal cerebellum in congenital OMA type Cogan are miss-
ing and (2) cerebellar cysts have been never reported in these
disorders [23, 24]. Other disorders associated with OMA such
as ataxia teleangiectasia and ataxia with oculomotor apraxia
types 1 and 2 can be easily excluded in our patients because of
the non-progressive course and the neuroimaging findings
(cerebellar cysts and dysplasia vs. cerebellar atrophy) [25].
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Recently, OMA has been reported in an 8.5-year-old, fully
ambulant male with proximal muscle weakness, severe myo-
pia, cerebellar cysts, a CK value of 1,500 U/L and mutations
in ISPD [26]. To our knowledge, this is the only
dystroglycanopathy patient with OMA reported so far. The
phenotype of α-dystroglycanopathies includes characteristi-
cally clinical and laboratory evidence of muscle involvement.
Muscle involvement presents as weakness with prenatal or
postnatal onset, affects predominantly the proximal muscles
and may cause a variable degree of motor impairment ranging
from walking with support to almost absent motor develop-
ment [3]. Hypotonia, contractures and scoliosis are additional
frequent features in children with dystroglycanopathy, as are
increased CK values (commonly, >7-fold higher than control
values) [3, 5]. The peculiarity of our series of patients is the
absence of clinical signs of muscle weakness. Therefore, a
muscle biopsy did not appear indicated, although three
children showed a slight CK elevation (not higher than 2-
fold normal values). In dystroglycanopathies, muscle involve-
ment may be isolated or associated with concomitant affection
of the central nervous system (CNS) and eyes [3]. CNS and
eye involvement are variable and range from mild intellectual
disability to absent motor and cognitive development, micro-
cephaly and severe seizures and from myopia, juvenile cata-
racts to microphthalmia, buphthalmus, and retinal dysplasia,
respectively [3]. All our patients had mild to moderate intel-
lectual disability and delayed language development. Three
children also had a severe myopia.
Nonprogressive cerebellar ataxia and cerebellar cysts are
common features of GPR56-related encephalopathy [12, 27].
To our knowledge, however, OMA has never been reported in
GPR56 -related encephalopathy [12, 27]. A predominant cer-
ebellar syndrome with OMA, absence of muscle weakness,
and only mildly increased CK value is very unusual and has
Fig. 1 Midsagittal (a), axial (b ,
c), and coronal (d) T2-weighted
MR images of patient 1 at the age
of 3.8 years show multiple
cortical/subcortical cysts located
within the cerebellar vermis
(anterior and superior part) and
both cerebellar hemispheres
(posterior and superior parts).
Additional abnormalities
illustrated: hypoplasia of the
inferior part of the cerebellar
vermis (a), bilateral cerebellar
dysplasia (b–d), an enlarged
fourth ventricle with a peculiar
elongated and squared shape (a),
an elongated midbrain (a), and a
short pons (a)
Fig. 2 Axial (a) and midsagittal (b) T2-weighted MR images of patient
3 at the age of 1.8 years show multiple cortical/subcortical cysts located
within the cerebellar vermis (mostly anterior and superior part) and both
cerebellar hemispheres (mostly posterior and superior parts). Additional
abnormalities illustrated: hypoplasia of the inferior part of the cerebellar
vermis (b), bilateral cerebellar dysplasia (a), an enlarged fourth ventricle
with a peculiar elongated and squared shape (b ), and an elongated
midbrain (b)
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not been reported so far in dystroglycanopathies and GPR56 -
related encephalopathy.
Neuroimaging Phenotype
Cerebellar cysts are a rare finding in pediatric neuroimaging.
They are relatively specific for dystroglycanopathies [2], al-
though they have been occasionally reported in Aicardi syn-
drome [13, 14] and exceptionally in pontocerebellar hypoplasia
type 6 [15]. These disorders were excluded in our patients based
on history, clinical and neuroimaging findings. Additionally,
cerebellar cysts with cerebellar dysplasia, cerebellar hypoplasia,
and brain stem abnormalities have been reported in children with
GPR56 mutations [12]. However, patients with GPR56 muta-
tions have bilateral fronto-parietal polymicrogyria in an antero-
posterior distribution and bilateral patchy white matter changes,
which were absent in our children [12]. Genetic analysis did not
reveal mutations in GPR56 in all our patients.
Brain involvement in dystroglycanopathies often includes
morphological defects of the cerebellum, such as hypoplasia,
Fig. 3 Midsagittal (a), axial (b ,
c), and coronal (d) T2-weighted
MR images of patient 4 at the age
of 10.5 years show multiple
cortical/subcortical cysts located
within the cerebellar vermis
(mostly anterior and superior part)
and both cerebellar hemispheres
(mostly posterior and superior
parts). Additional abnormalities
illustrated: global hypoplasia of
the cerebellar vermis (a), bilateral
cerebellar dysplasia (b–d), an
enlarged fourth ventricle with a
peculiar elongated and squared
shape (a), and a prominent
interpeduncular fossa (b)
Fig. 4 Midsagittal (a), coronal
(b), and axial (c , d) T2-weighted
MR images of patient 6 at the age
of 4.3 years show multiple
cortical/subcortical cysts located
within the cerebellar vermis
(mostly posterior and superior
part) and both (right more than
left) cerebellar hemispheres
(mostly posterior and superior
parts). Additional abnormalities
illustrated: global hypoplasia of
the cerebellar vermis (a), bilateral
cerebellar dysplasia (b–d), an
enlarged fourth ventricle with a
peculiar elongated and squared
shape (a), and an elongated
midbrain (a)
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dysplasia, and cystic lesions [2, 5, 28–31]. Neuropathological
examinations revealed that cerebellar cysts in CMD are lined by
leptomeningeal tissue. They are most likely formed from the
subarachnoid spaces that were engulfed by the dysplastic cere-
bellar folia, particularly in the boundary between normal and
dysplastic cerebellar cortex [32, 33]. In all our patients, cerebellar
cysts were associated with cerebellar dysplasia and were located
within the most dysplastic cerebellar tissue (antero-superior part
of the vermis and postero-superior part of the hemispheres).
Cerebellar cysts are characteristic for dystroglycanopathies and
have been mostly described in patients with mutations within the
FKRP, POMT2 , POMGnT1, and LARGE genes [2].
In dystroglycanopathies, involvement of the cerebellum
may be isolated or variably associated with morphological
abnormalities of the brain stem and supratentorial structures
[2, 5]. Mercuri and colleagues reported on 15 children with
CMD due to impaired glycosylation of α-dystroglycan and
isolated cerebellar involvement [5]. All these children had
clinical muscle involvement (weakness) and markedly in-
creased CK (at least 5-fold higher than normal values). In
their study on neuroimaging findings in dystroglycanopathies,
Clement and coworkers included two children with cerebellar
cysts and pontine abnormalities but no obvious cortical
changes [2]. However, both patients had ventriculomegaly
and supratentorial white matter changes. No data about clin-
ical muscle involvement are reported. Finally, Messina and
colleagues also reported on four children with CMD and
isolated cerebellar involvement [34]. All these patients had
weakness, difficulty in swallowing and markedly increased
CK. Our patients did not have supratentorial involvement and
only three of them showed subclinical muscle involvement as
minimally increased CK.
Morphological brain stem anomalies in dystroglycanopathies
generally include pontine hypoplasia (different degree of severity
ranging from mild hypoplasia to flat pons such as in MEB or
WWS), fused colliculi, ventral pontine cleft in MEB, and ponto-
mesencephalic kinking in WWS [2, 9, 35]. These severe brain
stem abnormalities were not present in any of our patients. The
Fig. 5 Midsagittal (a), coronal
(b), and axial (c , d) T2-weighted
MR images of patient 7 at the age
of 11 months show multiple
cortical/subcortical cysts located
within the cerebellar vermis
(mostly anterior and superior part)
and both cerebellar hemispheres
(mostly posterior and superior
parts). Additional abnormalities
illustrated: hypoplasia of the
inferior part of the cerebellar
vermis (a), bilateral cerebellar
dysplasia (b–d), an enlarged
fourth ventricle with a peculiar
elongated and squared shape (a),
an elongated midbrain (a), and a
short pons (a)
Fig. 6 Venn diagram with schematic distribution of organ involvement
and presence of cerebellar cysts for selected α-dystroglycanopathies
phenotypes. Brain involvement includes clinical (e.g., intellectual disabil-
ity and seizures) and morphological (e.g., migrational abnormalities,
white matter changes, and ventriculomegaly) findings; muscle involve-
ment represents weakness; eye involvement includes, e.g.,
microphthalmia, retinal dysplasia, glaucoma, and congenital cataracts.
DPM2/3 dolichol-phosphate mannosyltransferase 2/3, FCMD Fukuya-
ma congenital muscular dystrophy, LGMD2I limb-girdle muscular dys-
trophy type 2I, MEB muscle-eye-brain disease, WWS Walker–Warburg
syndrome
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majority of them had less severe brain stem anomalies including
midbrain elongation and/or pontine shortness.
Supratentorial involvement characterizes the most severe
phenotypes of dystroglycanopathies such asWWS,MEB, and
FCMD [2, 5, 35]. Supratentorial involvement has a wide
spectrum of severity and ranges from mild ventriculomegaly,
diffuse periventricular white matter changes, and focal areas
of polymicrogyria to severe hydrocephalus, generalized white
matter changes and diffuse cortical structural abnormalities
including cobblestone lissencephaly and an almost absent
cortical mantle [2, 5, 9, 35]. Supratentorial involvement in
dystroglycanopathies is not consistent and occurs in 40–85 %
of the patients [2, 5]. In our patients, only one had a mild
ventriculomegaly as the only supratentorial involvement.
Genotype
Mutations in 15 genes have been shown to cause a
dystroglycanopathy phenotype, including POMT1 , POMT2 ,
POMGnT1 , FKTN , FKRP, LARGE , ISPD , B3GALNT2 ,
DPM2 , DPM3 , GTDC2 , B3GNT1 , TMEM5 , SGK196 , and
GMPPB [4, 9–11, 36–41]. We excluded mutations within the
first eight genes in all our patients, including all those genes that,
when mutated, have been so far related to cerebellar cysts in
neuroimaging. Mutations within the DPM2 and DPM3 genes
have been reported to cause a phenotype characterized by intrac-
table seizures, progressivemicrocephaly, andmarkedly increased
CK [4, 36, 37]. Mutations in GTDC2 , TMEM5, and SGK196
have been reported to cause WWS [10]. The phenotype of our
patients was not characterized by seizures, progressive micro-
cephaly, markedly increased CK or WWS. One child harboring
missense variants in B3GNT1 had cysts within the dysplastic
cerebellum but the brain malformation spectrum was wider and
included focal cobblestone lissencephaly of the occipital cortex
and hyperintense signal of the subjacent white matter [40]. In
some of the patients with mutations in GMPPB , cerebellar and
brain stem malformations have been reported [41]. In children
with mutations in GMPPB , however, cerebellar cysts have not
been found [38, 41]. Therefore, mutations in theDPM2 ,DPM3 ,
GTDC2, TMEM5 , SGK196 , B3GNT1 , and GMPPB genes are
very unlikely in our patients, although not formally excluded.
Only in about half of the dystroglycanopathy patients, a mutation
was found in the known genes [3–5]. Mutations in GPR56 and
LAMB1 are related to a cerebral malformation similar to CMD,
although not being a dystroglycanopathy itself [10, 38].
Mutations in GPR56 have been formally excluded in all our
patients. Mutations in LAMB1 have been recently shown to
cause a constellation of brain malformations including cortical
gyral and white matter signal abnormalities, severe cerebellar
dysplasia, brain stem hypoplasia, and occipital encephalocele in
four children with only mild ocular and muscular abnormal
findings [38]. In children with mutations in LAMB1, however,
cerebellar cysts have not been found.
Limitations
We are aware of some limitations in our study: the number of
patients is rather small, a formal, quantitative neurocognitive
evaluation was only performed in a minority of the patients, and
mutations within the newest teammates in α-dystroglyca-
nopathies were not formally excluded by direct genetic analysis
although cerebellar cysts have not been reported in patients
mutated in those genes.
Conclusions
We report on seven children with the same clinical and imag-
ing phenotype characterized by (1) brain involvement as a
cerebellar syndrome with ataxia, OMA and intellectual dis-
ability and (2) cerebellar cysts and cerebellar dysplasia. This
combination of clinical and neuroimaging findings is reminis-
cent of α-dystroglycanopathies. However, typical features of
α-dystroglycanopathies, such as clinical muscle involvement
and eye involvement were not or only inconsistently present
in our patients. Additionally, mutations in the most suitableα-
dystroglycanopathies genes were not found in our patients.
Other well-defined disorders that are phenotypically partially
matching with our patients were excluded based on the clin-
ical and/or neuroimaging phenotype or normal genotype. We
conclude that the peculiar combination of clinical and neuro-
imaging findings in our patients suggests that this phenotype
may represent a novel syndromic entity, perhaps within the
ever-growing dystroglycanopathy spectrum (Fig. 6).
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